A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy

References

• MauryS, ChevretS, ThomasX, et al. Addition of rituximab improves the outcome of adult patients with CD20-positive, Ph-negative, B-cell precursor acute lymphoblastic leukemia (BCP-ALL): results of the randomized Graall-R 2005 study. Blood. 2015;126(23):1. doi:10.1182/blood.V126.23.1.126138534
   PubMed Web of Science ®Google Scholar
• JabbourE, O’BrienS, RavandiF, KantarjianH. Monoclonal antibodies in acute lymphoblastic leukemia. Blood. 2015;125(26):4010–4016. doi:10.1182/blood-2014-08-59640325999456
   PubMed Web of Science ®Google Scholar
• AnsellSM, LesokhinAM, BorrelloI, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–319. doi:10.1056/NEJMoa141108725482239
   PubMed Web of Science ®Google Scholar
• KostiP, MaherJ, ArnoldJN. Perspectives on chimeric antigen receptor T-cell immunotherapy for solid tumors. Front Immunol. 2018;9:1104. doi:10.3389/fimmu.2018.0110429872437
   PubMed Web of Science ®Google Scholar
• NewickK, O’BrienS, MoonE, AlbeldaSM. CAR T cell therapy for solid tumors. Annu Rev Med. 2017;68:139–152. doi:10.1146/annurev-med-062315-12024527860544
   PubMed Web of Science ®Google Scholar
• WeberJS, D’AngeloSP, MinorD, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Phase 3 trial. Lancet Oncol. 2015;16(4):375–384. doi:10.1016/S1470-2045(15)70076-825795410
   PubMed Web of Science ®Google Scholar
• SchadendorfD, HodiFS, RobertC, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–1894. doi:10.1200/JCO.2014.56.273625667295
   PubMed Web of Science ®Google Scholar
• FuchsCS, OzgurogluM, BangYJ, et al. Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal junction cancer (GC): update from the phase III KEYNOTE-061 trial. J Clin Oncol. 2020;38(15):4503.
   Web of Science ®Google Scholar
• SahinU, KoslowskiM, DhaeneK, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14:7624–7634. doi:10.1158/1078-0432.CCR-08-154719047087
   PubMed Web of Science ®Google Scholar
• TanakaM, ShibaharaJ, FukushimaN, et al. Claudin-18 is an early-stage marker of pancreatic carcinogenesis. J Histochem Cytochem. 2011;59(10):942–952. doi:10.1369/002215541142056921832145
   PubMed Web of Science ®Google Scholar
• SoiniY, TakasawaA, EskelinenM, et al. Expression of claudins 7 and 18 in pancreatic ductal adenocarcinoma: association with features of differentiation. J Clin Pathol. 2012;65(5):431–436. doi:10.1136/jclinpath-2011-20040022396552
   PubMed Web of Science ®Google Scholar
• WollS, SchlitterAM, DhaeneK, et al. Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer. 2014;134(3):731–739. doi:10.1002/ijc.2840023900716
   PubMed Web of Science ®Google Scholar
• TureciO, Mitnacht-KrausR, WollS, YamadaT, SahinU. Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology. 2019;8(1):e1523096. doi:10.1080/2162402x.2018.152309630546962
   PubMed Web of Science ®Google Scholar
• SchulerMH, ZvirbuleZ, LordickF, et al. Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas. J Clin Oncol. 2013;31(15):4080. doi:10.1200/jco.2013.31.15_suppl.4080
   Web of Science ®Google Scholar
• SahinU, SchulerM, RichlyH, et al. A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. Eur J Cancer. 2018;100:17–26. doi:10.1016/j.ejca.2018.05.00729936063
   PubMed Web of Science ®Google Scholar
• ZhuG, FolettiD, LiuX, et al. Targeting CLDN18.2 by CD3 bispecific and ADC modalities for the treatments of gastric and pancreatic cancer. Sci Rep. 2019;9(1):8420. doi:10.1038/s41598-019-44874-031182754
   PubMed Web of Science ®Google Scholar
• ChasovV, ZaripovM, MirgayazovaR, et al. Promising new tools for targeting p53 mutant cancers: humoral and cell-based immunotherapies. Front Immunol. 2021;12:3223. doi:10.3389/fimmu.2021.707734
   Web of Science ®Google Scholar
• PerezP, HoffmanRW, ShawS, BluestoneJA, SegalDM. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature. 1985;316(6026):354–356. doi:10.1038/316354a03160953
   PubMed Web of Science ®Google Scholar
• HoffmanL, GoreL. Blinatumomab, a bi-specific anti-CD19/CD3 BiTE® antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications. Front Oncol. 2014;4:63. doi:10.3389/fonc.2014.0006324744989
   PubMedGoogle Scholar
• WuZ, CheungNV. T cell engaging bispecific antibody (T-BsAb): from technology to therapeutics. Pharmacol Ther. 2018;182:161–175. doi:10.1016/j.pharmthera.2017.08.00528834699
   PubMed Web of Science ®Google Scholar
• VonderheideRH, GlennieMJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res. 2013;19(5):1035–1043. doi:10.1158/1078-0432.CCR-12-206423460534
   PubMed Web of Science ®Google Scholar
• QiX, LiF, WuY, et al. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity. Nat Commun. 2019;10(1):2141. doi:10.1038/s41467-019-10088-131105267
   PubMed Web of Science ®Google Scholar
• CorrentiCE, LaszloGS, de van der SchuerenWJ, et al. Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. Leukemia. 2018;32(5):1239–1243. doi:10.1038/s41375-018-0014-329588544
   PubMed Web of Science ®Google Scholar
• SuntharalingamG, PerryMR, WardS, et al. Cytokine storm in a Phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355(10):1018–1028. doi:10.1056/NEJMoa06384216908486
   PubMed Web of Science ®Google Scholar
• JabbourEJ, GokbugetN, KantarjianHM, et al. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer. 2019;125(23):4181–4192. doi:10.1002/cncr.3233531433496
   PubMed Web of Science ®Google Scholar
• DombretH, ToppMS, SchuhAC, et al. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60(9):2214–2222. doi:10.1080/10428194.2019.157687230947585
   PubMed Web of Science ®Google Scholar
• LofflerA, KuferP, LutterbuseR, et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95(6):2098–2103. doi:10.1182/blood.V95.6.209810706880
   PubMed Web of Science ®Google Scholar
• VonderheideRH, FlahertyKT, KhalilM, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25(7):876–883. doi:10.1200/Jco.2006.08.331117327609
   PubMed Web of Science ®Google Scholar
• DubrotJ, MilheiroF, AlfaroC, et al. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immun. 2010;59(8):1223–1233. doi:10.1007/s00262-010-0846-9
   PubMed Web of Science ®Google Scholar
• PollardJW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4(1):71–78. doi:10.1038/nrc125614708027
   PubMed Web of Science ®Google Scholar
• KitamuraT, QianBZ, PollardJW. Immune cell promotion of metastasis. Nat Rev Immunol. 2015;15(2):73–86. doi:10.1038/nri378925614318
   PubMed Web of Science ®Google Scholar
• JordanKR, AmariaRN, RamirezO, et al. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunother. 2013;62(11):1711–1722. doi:10.1007/s00262-013-1475-x24072401
   PubMed Web of Science ®Google Scholar
• KumarV, PatelS, TcyganovE, GabrilovichDI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208–220. doi:10.1016/j.it.2016.01.00426858199
   PubMed Web of Science ®Google Scholar
• GrothC, HuX, WeberR, et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer. 2019;120(1):16–25. doi:10.1038/s41416-018-0333-130413826
   PubMed Web of Science ®Google Scholar
• HodiFS, O’DaySJ, McDermottDF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med. 2010;363(8):711–723. doi:10.1056/NEJMoa100346620525992
   PubMed Web of Science ®Google Scholar
• WaiteJC, WangB, HaberL, et al. Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy. Sci Transl Med. 2020;12(549):eaba2325. doi:10.1126/scitranslmed.aba232532581132
   PubMed Web of Science ®Google Scholar